1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Formycon Gets UK Nod For Eylea Biosimilar

Teva-Partnered Ahzantive Version Of Aflibercept Receives MHRA Approval

 
• By Dave Wallace

Formycon has celebrated receiving a UK approval for its Ahzantive biosimilar version of Eylea, setting up a launch from partner Teva – which has already seen success in the UK market with the partners’ Lucentis biosimilar, Ongavia.

Formycon has another UK ophthalmic biosimilar approval (Shutterstock)

Formycon has received approval from the UK Medicines and Healthcare products Regulatory Agency for its FYB203 aflibercept biosimilar rival to Eylea, with the product approved under the name Ahzantive.

The ophthalmic biosimilar – approved to treat age-related neovascular (wet) macular degeneration, diabetic macular edema, visual impairment due to myopic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Medicines UK’s Samuels: Off-Patent Drugs Are Finally Gov’s Priority But The Picture Still ‘Nuanced’

 
• By Urtė Fultinavičiūtė

The importance of generic and biosimilar medicines is being recognized by the UK government for the first time. But, as Medicines UK’s CEO Mark Samuels tells Generics Bulletin, companies are still facing multiple hurdles in the market.

BC Partners Bids For Biogaran Buyout – But Will It Face French Pushback?

 
• By Dave Wallace

Private equity firm BC Partners has revealed that it is in exclusive negotiations to acquire Servier’s French generics and biosimilars business Biogaran. But with France’s government having expressed opposition to the sale, could there be strings attached?

Roche Braces For Late 2026 Biosimilar Wave

 
• By Dean Rudge

Roche expects biosimilars to Perjeta and Xolair by the end of 2026, marking a key inflection point for two of its major franchises. Shanghai Henlius Biotech leads development for pertuzumab, while Celltrion is positioned as the frontrunner for omalizumab.

Sandoz Strikes $300m Deal With Just-Evotec For French Biosimilars Site

 
• By Dave Wallace

Sandoz has made yet another major move to further bolster its booming biosimilars business, striking a $300m deal to acquire outright a French development and manufacturing facility from existing biosimilars partner Just-Evotec Biologics.

More from Business